VRX Stock Ownership Activity

VALEANT PHARMACEUTICALS INTL 13F holders

No value investing guru has made any change to the VALEANT PHARMACEUTICALS INTL (VRX) position according to the gurus' latest SEC quarterly report(s).

Which gurus or hedge funds are buying VRX now?

According to the latest SEC filing(s) VALEANT PHARMACEUTICALS INTL (VRX) has not been purchased by any super investor.

To see more about who is investing in VALEANT PHARMACEUTICALS INTL (VRX), please go to the VRX ownership page.

2015 Q3 (8 results)
Leon Cooperman
buy
+484,915
+1.75%
0.00%
Stephen Mandel
+40.52%
+2,151,637
+1.71%
5.94%
Ole Andreas Halvorsen
+8.16%
+320,122
+0.26%
2.90%
Francois Rochon
+4.14%
+4,979
+0.18%
4.50%
Nathaniel Simons
+0.11%
+1,457
+0.01%
0.00%
Ravenel Boykin Curry IV
-1.37%
-29,050
-0.04%
1.64%
Glenn Greenberg
-2.16%
-76,948
-0.70%
19.76%
James Crichton
-100.00%
-350,000
-4.33%
0.00%
AVG reported price*: $178.38
2015 Q2 (8 results)
Ole Andreas Halvorsen
+13.76%
+558,395
+0.47%
3.87%
Nathaniel Simons
-0.10%
-1,403
-0.01%
6.99%
Glenn Greenberg
-2.99%
-176,006
-1.13%
36.57%
Stephen Mandel
-4.66%
-259,317
-0.26%
5.24%
Ravenel Boykin Curry IV
-9.52%
-359,951
-0.31%
2.99%
Francois Rochon
-21.87%
-33,698
-1.50%
5.35%
Jeffrey Ubben
-22.65%
-3,116,627
-5.14%
12.45%
James Crichton
-36.36%
-200,000
-1.97%
0.00%
AVG reported price*: $222.15
2015 Q1 (9 results)
Bill Ackman
buy
+16,650,212
+25.84%
22.09%
Francois Rochon
buy
+104,004
+6.70%
4.52%
Nathaniel Simons
+23.95%
+259,666
+1.39%
7.21%
James Crichton
+3.77%
+17,800
+0.23%
5.60%
Ravenel Boykin Curry IV
-3.39%
-93,451
-0.10%
1.97%
Glenn Greenberg
-4.07%
-249,593
-1.51%
35.64%
Stephen Mandel
-32.50%
-2,681,426
-2.27%
4.72%
Ole Andreas Halvorsen
-55.29%
-5,018,664
-3.86%
3.12%
Quincy Lee
-100.00%
-149,975
-9.88%
0.00%
AVG reported price*: $198.62
2014 Q4 (8 results)
James Crichton
buy
+286,200
+7.49%
4.05%
Jeffrey Ubben
+2.43%
+460,000
+0.41%
17.38%
Ravenel Boykin Curry IV
-0.29%
-11,392
-0.01%
2.11%
Glenn Greenberg
-6.98%
-459,973
-2.29%
30.53%
Ole Andreas Halvorsen
-8.94%
-890,683
-0.59%
5.96%
Stephen Mandel
-24.90%
-1,996,589
-1.67%
3.68%
Nathaniel Simons
-31.44%
-497,347
-1.94%
4.23%
Frederick (Shad) Rowe
-100.00%
-20,000
-0.64%
0.00%
AVG reported price*: $143.11
2014 Q3 (7 results)
Frederick (Shad) Rowe
buy
+20,000
+0.68%
0.00%
Quincy Lee
+9.41%
+14,785
+0.70%
5.76%
Stephen Mandel
+8.89%
+896,490
+0.47%
5.76%
Glenn Greenberg
+8.86%
+536,140
+2.61%
32.02%
Ravenel Boykin Curry IV
+4.13%
+155,823
+0.08%
1.99%
Nathaniel Simons
+0.02%
+347
+0.00%
5.65%
Ole Andreas Halvorsen
-15.75%
-1,863,242
-0.98%
5.25%
AVG reported price*: $131.20
2014 Q2 (7 results)
Ravenel Boykin Curry IV
buy
+2,167,549
+1.88%
1.08%
Quincy Lee
+106.59%
+115,000
+3.70%
7.17%
Ole Andreas Halvorsen
+27.27%
+2,534,789
+1.40%
6.51%
Nathaniel Simons
+15.12%
+207,737
+0.74%
5.60%
Stephen Mandel
+14.44%
+1,272,748
+0.67%
5.30%
Glenn Greenberg
+8.19%
+457,884
+2.33%
30.78%
Daniel Loeb
-100.00%
-250,000
-0.41%
0.00%
AVG reported price*: $126.12
47 of 116

Shares, change to shares, sold shares - split-adjusted.

Reported price - this doesn't represent the actual buy or sell price.
It is the split-adjusted price of the security as of the last day of the reported period.

Value or Price - If the security is completely sold out, we show the reported value (or price) prior to the actual period.